Sagent Pharmaceuticals will acquire the remaining 50% interest of its joint venture partner, Chengdu Kanghong Pharmaceuticals Co. Ltd., in the Kanghong Sagent (Chengdu) Pharmaceutical Corp. Ltd. (KSCP) joint venture. KSCP will become a wholly-owned subsidiary of Sagent. The $25 million acquisition, subject to customary closing conditions, is expected to close within the next several months.   “We originally formed our joint venture in 2006 to construct and operate an FDA and cGMP compliant...